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Abstract
Background: Comparative performance of the traditional propensity score (PS) and high-dimensional propensity
score (hdPS) methods in the adjustment for confounding by indication remains unclear. We aimed to identify
which method provided the best adjustment for confounding by indication within the context of the risk of
diabetes among patients exposed to moderate versus high potency statins.
Method: A cohort of diabetes-free incident statins users was identified from the Quebec’s publicly funded medico-
administrative database (Full Cohort). We created two matched sub-cohorts by matching one patient initiated on a
lower potency to one patient initiated on a high potency either on patients’ PS or hdPS. Both methods’ performance
were compared by means of the absolute standardized differences (ASDD) regarding relevant characteristics and by
means of the obtained measures of association.
Results: Eight out of the 18 examined characteristics were shown to be unbalanced within the Full Cohort. Although
matching on either method achieved balance within all examined characteristic, matching on patients’ hdPS created
the most balanced sub-cohort. Measures of associations and confidence intervals obtained within the two matched
sub-cohorts overlapped.
Conclusion: Although ASDD suggest better matching with hdPS than with PS, measures of association were almost
identical when adjusted for either method. Use of the hdPS method in adjusting for confounding by indication within
future studies should be recommended due to its ability to identify confounding variables which may be unknown to
the investigators.
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Background
Observational studies provide real world information on
drug use and their potential effect on health outcomes
but are prone to confounding by indication [1–4]. The
traditional propensity score (PS) method is often used to
control for confounding by indication. It represents “the
conditional probability of assignment to a particular treat-
ment given a vector of observed covariates” and is gener-
ally obtained thanks to a logistic regression model [5].
The high-dimensional propensity score (hdPS) method
has recently been proposed and has been rapidly and
widely adopted to address confounding by indication
[6, 7]. Unlike the PS method which is limited to
investigator-specified covariates; the hdPS method also
uses a computerized algorithm to select a large number
of potential confounders contained within the exam-
ined database [5, 7].
It is of interest to compare the performance of these
two methods in controlling for confounding by indica-
tion to inform the design of future observational studies.
Performance of both methods may be compared using
two distinct approaches, 1) by examining the balance
achieved on key potential confounders between sub-
cohorts matched on these two scores [4, 8–11], and 2)
by comparing the measures of associations obtained
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from the matched sub-cohorts to a gold standard com-
parator [7, 12–14].
Recently, results of a meta-analysis of randomized
controlled trials (RCT) have found that exposure to
higher statin doses might be associated with higher risks
of diabetes (Odds ratio [OR] =1.12 [95 % confidence in-
tervals (CI) 1.04–1.22]) [15]. Although results obtained
from observational studies have been conflicting [16],
four out of five published studies found a small in-
creased but statistically significant dose-dependent rela-
tionship [17–20]. However, it is possible that in those
observational studies, patients at higher risk of diabetes
were more likely to be initiated on higher statins doses:
a classic example of confounding by indication offering
an excellent opportunity to compare the relative per-
formance of these two scores. In this study, we aim to
compare the performance of the PS and hdPS methods




This study was performed using medico-administrative
databases from the province of Quebec, Canada. Quebec
is the second most populated province in Canada, with
more than 8 million inhabitants [21]. A unique identifi-
cation number is assigned to every individual, and all
diagnoses and all health services provided are systemat-
ically recorded within the Régie de l’assurance maladie
du Québec (RAMQ) databases. Pharmaceutical claims
are also recorded but only for residents covered by the
RAMQ public drug insurance plan. Information was ob-
tained from the Quebec physician’s service and claims
databases (i.e. RAMQ databases) and the Quebec hospi-
talisation databases (i.e., Maintenance et Exploitation
des Données pour l’Étude de la Clientèle Hospitalière
[MED-ECHO] databases), which have previously been
validated [22–25]. For this study we used three RAMQ
databases (i.e., the Demographic, Medical Services and
Claims and Pharmaceutical databases) and three MED-
ECHO databases (i.e. the Hospitalisation Descriptions,
Diagnoses and Intervention databases). Patient records
were linked across all databases by use of the unique
identification number. The identification numbers were
encrypted to protect patient confidentiality. Access to data
was granted by the Commission d’accès à l’information
and the protocol was approved by the Centre hospitalier
de l’Université de Montréal ethics’ committee.
Full Cohort
RAMQ provided us with a cohort of 800,551 incident
statin users; the date of the first statin dispensation was
defined as the cohort entry date. Patients were consid-
ered to be incident statin users if they did not have a
claim for a statin dispensation in the year prior to the
cohort entry date. Eligible patients had: 1) to have been
newly initiated on either simvastatin, lovastatin, prava-
statin, fluvastatin, atorvastatin or rosuvastatin between
January 1st 1998 and December 31st 2010, 2) to be cov-
ered by the RAMQ public drug insurance plan for at
least a year prior to the cohort entry date and 3) to be at
least 40 years of age at the cohort entry date. We ex-
cluded every patient who, in the year prior or on the
cohort entry date: 1) received any other cholesterol low-
ering drug dispensation (including niacin, cerivastatin or
a combination statin drug); 2) received a dispensation
for drugs used in the treatment of diabetes (WHO ATC
A10) [26]; 3) received a diagnosis of diabetes (ICD-9
code: 250.x; ICD-10 codes: E10.x – E14.x); 4) were ad-
mitted in a long-term care facility or 5) received >1 sta-
tin dispensation on the cohort entry date. Patients who
met both inclusion and exclusion criteria were entered
within the Full Cohort.
Exposure status
Patients were categorized into two categories based on
the dose and relative potency of the first statin dispensa-
tion they received [18, 27]. Patients whose first statin
dispensation was for a daily dose of ≥10 mg of rosuvas-
tatin, ≥20 mg of atorvastatin or ≥40 mg of simvastatin
formed the high potency group and remaining patients
formed the lower potency group.
Outcome status
Every patient who received either a dispensation of a
drug used in the treatment of diabetes (WHO ATC A10)
or a diagnosis of diabetes (ICD-9 code: 250.x; ICD-10
codes: E10.x – E14.x) within the 2 years following the
cohort entry date was defined as a case, all other pa-
tients were considered to be diabetes-free.
Propensity score method
We used the same list of variables that were used by
Dormuth and colleagues to create the PS model [18].
This list included the following covariates: patients’ sex,
age and poverty level status (yes versus no) at the cohort
entry date, year of entry within the cohort (as a categor-
ical variable), medical resource utilization variables (≥1
hospitalisation, ≥5 outpatient visits, ≥5 distinct drugs
dispensed to the patient, all within the year prior to the
cohort entry date), drug dispensation variables (dispen-
sation of loop diuretics, dispensation of acetaminophen,
dispensation of calcium blockers, dispensation of beta-
blockers, dispensation of angiotensin receptor blockers
and dispensation of angiotensin converting enzyme in-
hibitors, all in the year prior to the cohort entry date)
and comorbidity variables (hypertension, hypercholester-
olemia, myocardial infarction (MI), stroke, peripheral
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vascular disease (PVD), congestive heart failure, coron-
ary artery bypass graft, and percutaneous coronary
intervention (PCI), all in the year prior to the cohort
entry date).
Following the selection of the PS model, patients’ PS
were assessed for all patients included within the Full
Cohort. Trimming was performed and patients located
within non-overlapping regions of the PS distribution
were excluded from the analysis, all other patients were
eligible for inclusion within the Matched PS Sub-Cohort
[28]. Lower potency controls were found for patients in
the high potency group using a greedy, nearest neighbor
1:1 matching algorithm. Matching occurred if the differ-
ence in the logit of PS between nearest neighbors was
within a caliper width equal to 0.2 times the standard
deviation (SD) of the logit of the PS [29]. Patients se-
lected by the matching algorithm were included within
the Matched PS Sub-Cohort.
High-dimensional propensity score method
hdPS were estimated for all patients included in the Full
Cohort [7]. Detailed description of the hdPS method can
be found elsewhere [7]. Briefly, the construction of the
hdPS model involves two processes, 1) investigators se-
lect covariates to be forced within the hdPS model (simi-
lar to what is done within an investigator-specified PS
model) and 2) the hdPS algorithm selects an additional
list of covariates measured within the selected data di-
mensions based on their multiplicative bias assessment
which is then also included within the final hdPS model.
Within this study, estimation of patients’ hdPS were
conducted using the default setting of the SAS hdPS
macro v.1 (i.e., top 200 most prevalent variables per data
dimensions, top 500 binary empirical covariates based
on multiplicative bias assessment).
We structured the data collected from the year prior
to the cohort entry date from the following 6 data di-
mensions: 1) drugs dispensed in an outpatient setting,
2) physician claims codes for inpatient and outpatient
procedures, 3) physician claims for inpatient and out-
patient diagnostic codes, 4) specialty of the physician
providing care, 5) hospitalisation discharge data for
inpatient procedure codes and 6) hospitalisation dis-
charge data for inpatient diagnostic code.
In addition to the 500 variables selected by the default
option of the hdPS algorithm [7], we forced the follow-
ing covariates within the hdPS model: patients’ sex, age
and poverty level status (yes versus no) at the cohort
entry date, year of entry within the cohort (as a categor-
ical variable), medical resource utilization variables (≥1
hospitalisation, ≥5 outpatient visits, ≥5 distinct drugs
dispensed to the patient, all within the year prior to the
cohort entry date). These variables were forced in the
model since they could not be selected by the SAS hdPS
algorithm v.1 we were using. Trimming was performed
and patients located within non-overlapping regions of
the hdPS distribution were excluded from the analysis
[28], all other patients were eligible for inclusion within
the Matched hdPS Sub-Cohort. Lower potency controls
were found for patients in the high potency group using
a greedy, nearest neighbor 1:1 matching algorithm.
Matching occurred if the difference in the logit of hdPS
between nearest neighbors was within a caliper width
equal to 0.2 times the SD of the logit of the hdPS [29].
Patients selected by the matching algorithm were in-
cluded within the Matched hdPS Sub-Cohort.
Statistical analyses
Absolute standardized differences (ASDD), defined as
the absolute between group difference over the pooled
SD of the two groups, were used to compare patient
characteristics between patients exposed to a high
potency versus lower potency statin within the Full
Cohort and both sub-cohorts [4, 8–11]. ASDD < 0.1
are generally assumed to indicate good balance be-
tween groups [2, 10]. Discrete data are presented in
absolute and relative values (n [%]) and continuous
data are presented as mean (SD). OR (95%CI) of dia-
betes occurrence in the high over lower potency sta-
tin groups were estimated within the Full Cohort and
within both matched sub-cohorts; no adjustment be-
yond matching was performed.
All statistical analyses were conducted with SAS
version 9.3 (SAS Institute, Cary, North Carolina).
Results
Characteristics of the patients included within the Full
Cohort
Figure 1 shows the flow chart of patients included within
the Full Cohort, the Matched PS Sub-Cohort and the
Matched hdPS Sub-Cohort.
Baseline characteristics of the Full Cohort are shown
in Table 1. Among the 404,129 patients included within
the Full Cohort, 264,947 patients (65.6 %) were dis-
pensed a lower potency statin and 139,182 patients
(34.4 %) were dispensed a high potency statin on the co-
hort entry date. About half of patients (192,964 [47.8 %])
were males and the average age was 65.2 years (SD
11.0). Among the 18 examined patient characteristics,
eight (44.4 %) were shown to have an ASDD > 0.1 indi-
cating the presence of unbalance. History of a PCI
(ASDD = 0.30) and history of a MI (ASDD = 0.27), both
in the year prior to the cohort entry date, showed the
greatest degree of imbalance (Table 1). In addition, onset
of diabetes within 2-years follow-up was identified in
12,978 patients (3.2 %) of the 404,129 patients included
within the Full Cohort.
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Characteristics of patients included within the Matched
PS Sub-Cohort
PS were calculated for all 404,129 patients included
within the Full Cohort (kernel density PS curves for all
patients included within the Full Cohort are provided in
Additional file 1). Fifty-five (0.0 %) patients, 33 (0.0 %)
lower potency and 22 (0.0 %) high potency, had PS lo-
cated within non-overlapping regions and were excluded
from the analysis. Among the remaining 404,074 pa-
tients, we matched 119,857 patients (29.7 %) initiated on
a high potency statin to 119,857 patients (29.7 %) initi-
ated on a lower potency statin based on their individual
PS; selected patients formed the Matched PS Sub-Cohort
(Fig. 1). This sub-cohort was comprised of 119,931 male
patients (50.0 %) and the average age was 64.7 years (SD
11.2) (Table 2). Balance was obtained for all 18 examined
patient characteristics (ASDD ranged from 0.002 to
0.031 with an average of 0.015).
Characteristics of patients included within the Matched
hdPS Sub-Cohort
Three hundred and one (0.1 %) patients, 54 (0.0 %)
lower potency and 247 (0.1 %) high potency, had hdPS
located within non-overlapping regions and were
excluded from the analysis (kernel density hdPS curves
for all patients included within the Full Cohort are
provided in Additional file 2). Among the remaining
403,828 patients, we matched 116,014 patients (28.7 %)
initiated on a high potency statin to 116,014 patients
(28.7 %) initiated on a lower potency statin based on
their individual hdPS; selected patients formed the
Matched hdPS Sub-Cohort (Fig. 1).
Patients included within the Matched hdPS Sub-
Cohort were on average 64.6 years old (SD 11.2) and
116,688 of them were males (50.3 %) (Table 3). Balance
was obtained in all 18 examined patient characteristics,
whether or not they were forced within the hdPS model
(ASDD ranged from 0.001 to 0.023 with an average of
0.008).
Performance of the PS and hdPS in adjusting for
confounding by indication
As mentioned previously, performance of both methods
in adjusting for confounding by indication was tested by
two distinct approaches, 1) by comparing the ASDD ob-
tained within both sub-cohorts and 2) by comparing the
adjusted OR of diabetes occurrence in the high over
lower potency statin groups estimated by the logistic
Fig. 1 Patient flow-chart within the study. hdPS, High-dimensional propensity score; PS, Propensity score
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regression model used within the Full Cohort and both
matched sub-cohorts. Figure 2 shows the direct compari-
son of the ASDD for the examined patient characteristics
within the Full Cohort, the Matched PS Sub-Cohort and
the Matched hdPS Sub-Cohort. Results indicate that both
matched sub-cohorts were more balanced than the un-
matched Full Cohort. Although the Matched PS Sub-
Cohort provided greater balance on three of the 18 exam-
ined patient characteristics (MI, hypercholesterolemia,
and PVD), overall, the Matched hdPS Sub-Cohort
achieved the most balanced sub-cohort (average ASDD=
0.008 and average ASDD = 0.015 in the Matched hdPS
Sub-Cohort and Matched PS Sub-Cohort, respectively).
Measures of associations obtained within the Full Cohort
and the two matched sub-cohorts indicated that patients
in the high potency group had higher odds of developing
diabetes within 2-years follow-up. Results obtained within
both sub-cohorts overlapped (OR = 1.10 [95 % CI 1.05–
1.15] within the Matched PS Sub-Cohort and OR = 1.13
[95 % CI 1.08–1.19] within the Matched hdPS Sub-Cohort)
but both were lower than those obtained within the Full
Cohort (OR = 1.22 [95%CI 1.18–1.27]).
Discussion
As expected, overall patient profiles within the Full Cohort
showed imbalance on many key baseline characteristics
suggesting the presence of confounding by indication.
Such results would tend to indicate the presence of bias
within measures of associations estimated within the
Full Cohort if appropriate adjustment were not used in
the analyses.
In their original paper, Schneeweiss et al. [7] assessed
the performance of the hdPS method by comparing
measures of associations adjusted for patients’ hdPS to
the results of a RCT. By showing that the adjusted mea-
sures of association were closer to the results of the
RCT than the crude measure of association, they showed
that hdPS method had improved the adjustment for con-
founding by indication within their study. Performance
of the hdPS method has been assessed by others using
the same approach and their results also supported its
use [12–14]. Measures of association obtained within
both matched sub-cohorts were closer to the null (OR =
1.10 [95%CI 1.05–1.15] within the Matched PS Sub-
Cohort and OR = 1.13 [95%CI 1.08–1.19] within the
Matched hdPS Sub-Cohort) than within the Full Cohort
(OR = 1.22 [95%CI 1.18–1.27]). However, since the CIs
obtained from both methods overlap with each other
and are as precise, their performance cannot be differen-
tiated based solely on this criterion.
However, performance based on the level of balance
achieved within matched sub-cohorts does not require
Table 1 Demographic characteristics and comorbidity status of the Full Cohort at baseline
Low potency n (%) High potency n (%) Absolute standardized differences
264,947 (100.0) 139,182 (100.0)
Age, mean (SD)a 65.6 (10.9) 64.5 (11.3) 0.098
Male sex 118,262 (44.6) 74,702 (53.7) 0.181
At least 5 medical outpatient visits 170,234 (64.3) 77,032 (55.4) 0.182
At least 1 hospitalisation 59,591 (22.5) 45,777 (32.9) 0.234
Myocardial infarction 15,056 (5.7) 18,899 (13.6) 0.270
Stroke 7150 (2.7) 5480 (3.9) 0.069
Hypertension 110,508 (41.7) 59,705 (42.9) 0.024
Hypercholesterolemia 88,458 (33.4) 47,005 (33.8) 0.008
Peripheral vascular disease 5446 (2.1) 3338 (2.4) 0.023
Congestive heart failure 11,337 (4.3) 8830 (6.3) 0.092
Coronary artery bypass graft 3589 (1.4) 3189 (2.3) 0.070
Percutaneous coronary intervention 7742 (2.9) 14,089 (10.1) 0.295
Dispensation of loop diuretics 16,612 (6.3) 10,188 (7.3) 0.042
Dispensation of calcium blockers 64,569 (24.4) 32,192 (23.1) 0.029
Dispensation of beta-blockers 77,669 (29.3) 49,147 (35.3) 0.128
Dispensation of angiotensin receptor blockers 35,741 (13.5) 25,325 (18.2) 0.129
Dispensation of angiotensin converting enzyme inhibitors 52,563 (19.8) 36,030 (25.9) 0.144
At least 5 different drugs dispensed 151,395 (57.1) 84,503 (60.7) 0.073
Comorbidity status, drug dispensations and medical utilization rates were assessed in the year prior to the cohort entry date. Absolute standardized differences
are defined as the between group difference over the pooled standard deviation of the two groups
aAt the cohort entry date
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an additional comparator. Based on this second perform-
ance criterion, we showed that using both methods cre-
ated balanced matched sub-cohorts (i.e. ASDD were < 0.1
for all patient characteristics in both matched sub-cohort).
When directly comparing both sub-cohorts, use of the
hdPS method was favored since 14 out of the 18 examined
patient characteristics were more balanced within the
Matched hdPS Sub-Cohort than within the Matched PS
Sub-Cohort which should tend to lead to less biased mea-
sures of association within the Matched hdPS Sub-Cohort.
Seeing as the hdPS model adjusted for more variables than
the PS model, such a result was to be expected but it
needed to be verified in a situation where we have prior
knowledge on which confounders to adjust for. The re-
sults we show in this study support the idea that the
hdPS method may be used to adjust for confounding by
indication, but the possibility that residual confounding
remaining after this adjustment cannot be ruled out.
Our study has several strengths. First, we compared
the PS and hdPS method in a large cohort of incident
statin users showing substantial imbalance suggesting
the potential for confounding by indication. As such,
this provided an excellent situation in which to compare
the performance of both methods.
Second, our conclusions favored the hdPS method
when our study design should have favored the PS
method. Although all of the examined covariates were
forced within the PS model, only five investigator-
selected covariates were forced within the hdPS model
(only demographic, socio-economic and medical re-
source utilization variables were forced within the hdPS
model, all remaining covariates were selected by the
hdPS algorithm [n = 500]) [7]. Therefore, the hdPS
method performance was mainly achieved through the
use of the automated hdPS algorithm and not by investi-
gator choice.
Our study has also several limitations. First, we com-
pared patients on a relatively small number of baseline
patient characteristics. It is possible that the perform-
ance observed within the 18 prespecified patient char-
acteristics may not be representative of the overall
performance regarding all potential patient characteris-
tics. However, these variables were selected because we
believed, like others have [18], that they could lead to
confounding by indication and our results show that
the hdPS method achieved substantial balance within
all of these even though most were not forced within
the hdPS model.
Second, we defined unbalance as ASDD > 0.1. Al-
though this cut-off is frequently used [2, 10, 16], other
values could have been used as well. Regardless of the
cut-off value chosen, our results indicate that the hdPS
Table 2 Demographic characteristics and comorbidity status of the Matched PS Sub-Cohort at baseline
Low potency n (%) High potency n (%) Absolute standardized differences
119,857 (100) 119,857 (100)
Age, mean (SD)a 64.6 (11.2) 64.8 (11.2) 0.021
Male sex 59,690 (49.8) 60,241 (50.3) 0.009
At least 5 medical outpatient visits 68,696 (57.3) 69,017 (57.6) 0.005
At least 1 hospitalisation 29,527 (24.6) 31,129 (26.0) 0.031
Myocardial infarction 8457 (7.1) 8527 (7.1) 0.002
Stroke 3824 (3.2) 4219 (3.5) 0.018
Hypertension 49,335 (41.2) 50,719 (42.3) 0.023
Hypercholesterolemia 38,760 (32.3) 38,887 (32.4) 0.002
Peripheral vascular disease 2374 (2.0) 2691 (2.3) 0.018
Congestive heart failure 5412 (4.5) 5852 (4.9) 0.017
Coronary artery bypass graft 1756 (1.5) 1988 (1.7) 0.016
Percutaneous coronary intervention 5255 (4.4) 4805 (4.0) 0.019
Dispensation of loop diuretics 7202 (6.0) 7775 (6.5) 0.020
Dispensation of calcium blockers 26,878 (22.4) 27,928 (23.3) 0.021
Dispensation of beta-blockers 35,805 (29.9) 36,741 (30.7) 0.017
Dispensation of angiotensin receptor blockers 21,228 (17.7) 21,776 (18.2) 0.012
Dispensation of angiotensin converting enzyme inhibitors 25,537 (21.3) 26,484 (22.1) 0.019
At least 5 different drugs dispensed 69,608 (58.1) 70,087 (58.5) 0.008
Comorbidity status, drug dispensations and medical utilization rates were assessed in the year prior to the cohort entry date. Absolute standardized differences
are defined as the between group difference over the pooled standard deviation of the two groups
aAt the cohort entry date
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method outperformed the PS method in achieving the
most balanced sub-cohort. Although this added level of
balance may not eliminate all biases within the observa-
tional study (i.e. information bias, unmeasured con-
founders, time-varying confounding), it will at least tend
to reduce the level of bias caused by these baseline
characteristics.
Third, no mechanism of action by which statins could
cause diabetes has been identified. Although we com-
pared both methods using a frequently used exposure
definition, we cannot claim that this exposure definition
reflects the true mechanism of action by which statins
could cause diabetes. It is possible that the results ob-
tained, had we used an exposure definition reflecting the
true mechanism of action, could have differed from
those obtained within this study. This also reflects the
fact that we do not know what the true measure of asso-
ciation between the exposure to statins and diabetes is.
As mentioned, traditionally the hdPS method has been
validated by comparing the crude and hdPS-adjusted
measures of association to a gold standard measure but
in this case, such a true gold standard is not available.
We recognize that this would not have been the case
had we conducted this comparison within an ordinary
simulation study in which the truth would be defined by
the investigators. However, as others have highlighted,
[7, 30] the hdPS method cannot be evaluated through
the use of ordinary simulation studies since its perform-
ance depends on the complexity and quantity of data
available to the hdPS algorithm, levels of which cannot
be reproduced within a fully artificial setting. In order to
circumvent this issue, Franklin et al. [30] recently pro-
posed that performance of the hdPS method compared
to the performance of the PS method be compared using
plasmode simulation studies. Using this framework,
Franklin et al. showed that an investigator-independent
hdPS method performed nearly as well as a fully speci-
fied PS model further supporting the use of the hdPS
method in situations where little prior knowledge re-
garding potential confounding variables is available [30].
Such an approach may be validated in future work
aimed at further evaluating the performance of the hdPS
method.
Fourth, our results show that hdPS trimming removed
slightly more patients than PS trimming (301 vs 55). Al-
though this could impact our conclusion regarding the
value of both methods, its impact should be marginal
since the total number of patients that were trimmed in
both settings remains trivial in comparison to the total
sample size of the Full Cohort.
Finally, we only examined the relative performance of
the PS and hdPS methods within a single context; the
Table 3 Demographic characteristics and comorbidity status of the Matched hdPS Sub-Cohort at baseline
Low potency n (%) High potency n (%) Absolute standardized differences
116,014 (100.0) 116,014 (100.0)
Age, mean (SD)a 64.6 (11.2) 64.6 (11.2) 0.002
Male sex 58,194 (50.2) 58,494 (50.4) 0.005
At least 5 medical outpatient visits 66,453 (57.3) 66,390 (57.2) 0.001
At least 1 hospitalisation 28,265 (24.4) 28,604 (24.7) 0.007
Myocardial infarction 7558 (6.5) 7995 (6.9) 0.015
Stroke 3620 (3.1) 3897 (3.4) 0.013
Hypertension 48,268 (41.6) 48,474 (41.8) 0.004
Hypercholesterolemia 37,486 (32.3) 37,841 (32.6) 0.007
Peripheral vascular disease 2293 (2.0) 2671 (2.3) 0.023
Congestive heart failure 5198 (4.5) 5479 (4.7) 0.012
Coronary artery bypass graft 1670 (1.4) 1661 (1.4) 0.001
Percutaneous coronary intervention 4590 (4.0) 4846 (4.2) 0.011
Dispensation of loop diuretics 7139 (6.2) 7256 (6.3) 0.004
Dispensation of calcium blockers 26,510 (22.9) 26,716 (23.0) 0.004
Dispensation of beta-blockers 33,901 (29.2) 34,389 (29.6) 0.009
Dispensation of angiotensin receptor blockers 20,345 (17.5) 20,876 (18.0) 0.012
Dispensation of angiotensin converting enzyme inhibitors 24,472 (21.1) 25,289 (21.8) 0.017
At least 5 different drugs dispensed 66,600 (57.4) 66,820 (57.6) 0.004
Comorbidity status, drug dispensations and medical utilization rates were assessed in the year prior to the cohort entry date. Absolute standardized differences
are defined as the between group difference over the pooled standard deviation of the two groups
aAt the cohort entry date
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results obtained within this study may not be generalizable
to other studies focusing on other exposure-disease asso-
ciations. Furthermore, we only compared the traditional
PS method estimated using a logistic regression model to
hdPS method, while other methods are also available
(e.g., classification and regression trees and boosting
methods) [31, 32]. Future work will be needed to com-
pare the relative performance of all these different
methods.
Conclusions
In conclusion, we recommend comparing the PS and
hdPS methods by means of their relative ability to select
balanced sub-cohorts over their adjustment potential
within ethiological studies. Although both methods ad-
equately adjusted for confounding by indication, we
cannot rule out the possibility that the hdPS method
will be dominant in other contexts since it has the
potential to identify confounders which are unknown
to the investigators.
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Fig. 2 Comparison of the level of balance achieved using the absolute standardized differences obtained within the Full Cohort, the Matched PS
Sub-Cohort and the Matched hdPS Sub-Cohort the examined patient characteristics. ACEI, Angiotensin converting enzyme inhibitors; ARB,
Angiotensin receptor blockers; BB, Beta-blockers; CABG, Coronary artery bypass graft; Calc blockers, Calcium blockers; CHF, Congestive heart failure;
hdPS, High-dimensional propensity score; PCI, Percutaneous coronary intervention; PS, Propensity score; PVD, Peripheral vascular disease
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